CC Diagnostics Completes Methica CC Clinical Validation Study with Groundbreaking Results

CC Diagnostics Completes Clinical Validation Study with Groundbreaking Results We are proud to announce the successful completion of our clinical validation study for Methica CC, a critical milestone in our mission to revolutionize cervical cancer diagnostics. Conducted with a large cohort using samples from the Dutch National Screening Program, the study provides robust, real-world evidence of our technology's performance while eliminating bias. Unprecedented Accuracy and Real-World Applicability The study demonstrated 97% sensitivity for cancer detection, significantly outperforming the Pap Smear by 21%. Importantly, this improved sensitivity was achieved without compromising specificity, ensuring a more accurate and reliable diagnostic tool for women’s health. By incorporating samples from the Dutch National Screening Program and conducting the study across multiple centers, we ensured that the results reflect real-world performance across diverse clinical settings. This approach underscores the broad applicability and scalability of our solution. A Leap Forward in Cervical Cancer Screening Our innovative technology addresses the limitations of traditional cervical cancer screening methods by providing enhanced detection rates, reducing false negatives, and offering earlier, more accurate diagnoses. This achievement positions CC Diagnostics at the forefront of innovation in women’s health and diagnostics. What’s Next? With this successful validation, we are now focused on the next steps toward regulatory approval and commercialization, bringing this life-saving technology to healthcare systems worldwide. We extend our heartfelt thanks to the UMCG, the participating study centers, and our collaborators and investors who contributed to this milestone. Together, we are making strides toward a future where cervical cancer is more effectively detected and treated.